COVID-19 Vaccines - 2025/2026

If you are included in the specific high-risk populations below, it is recommended that you receive a COVID-19 vaccine dose(s) as soon as it becomes available in the fall and should receive an additional dose in the spring. High-risk groups eligible for both fall and spring dose(s) include:

• adults 65 years of age and older
  • National Advisory Committee on Immunization (NACI) recommends that those 80 years and older should receive an additional dose of vaccine while those 65 to 79 years of age may receive an additional dose of vaccine in the spring.
• adult residents of long-term care homes and other congregate living settings for seniors
• individuals 6 months of age and older who are moderately to severely immunocompromised (due to an underlying condition or treatment); see the list below
• individuals 55 years and older who identify as First Nations, Inuit, or Métis and their non-Indigenous household members who are 55 years and older

People who are moderately to severely immunocompromised

People with the following conditions are considered to be moderately to severely immunocompromised and should receive both fall and spring doses:

• solid tumour or hematologic malignancies or treatments for these conditions
• solid-organ transplant and taking immunosuppressive therapy
• hematopoietic stem cell transplant (HSCT) (within 2 years of transplantation or taking immunosuppression therapy)
• immunocompromised due to chimeric antigen receptor (CAR) T cell therapy targeting lymphocytes
• moderate to severe primary immunodeficiency with associated humoral and/or cell-mediated immunodeficiency or immune dysregulation
• HIV with AIDS-defining illness or TB diagnosis in last 12 months before starting vaccine series, or severe immune compromise with CD4 ‹ 200 cells/µL or CD4<15%, or without HIV viral suppression
• recent treatment with the following categories of immunosuppressive therapies:
  • anti-B cell therapies (monoclonal antibodies targeting CD19, CD20 and CD22)
  • high-dose systemic corticosteroids
  • alkylating agents
  • antimetabolites
  • tumor-necrosis factor (TNF) inhibitors
  • other biologic agents that are significantly immunosuppressive
• chronic kidney disease on dialysis

Contact your health-care provider if you have received any of the following since your most recent COVID-19 vaccination(s):

• a hematopoietic stem cell transplant
• hematopoietic cell transplant (autologous or allogeneic)
• a (CAR)-T-cell therapy

You may be recommended to be re-vaccinated due to loss of immunity following transplant or therapy.